Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions

Join us for this year’s International Myeloma Foundation–sponsored symposium, where Brian G.M. Durie, MD; Philippe Moreau, MD; Bruno Paiva, PhD; S. Vincent Rajkumar, MD; and Jesús F. San-Miguel, MD, PhD, provide their perspective on how recent data can be integrated into practice to address current clinical questions and challenges in caring for patients with multiple myeloma.

Interact with these international experts as they debate these clinical questions and discuss how these challenges can affect therapeutic decisions faced by clinicians treating myeloma.

Register Now

Friday Satellite Symposium preceding the 59th ASH Annual Meeting & Exposition.


1:00 PM – 1:05 PM Welcome and Introduction
Brian G.M. Durie, MD, Program Director and Moderator

1:05 PM – 3:50 PM Case Discussions

  • Accurately Diagnosing MM: When Should Systemic Myeloma Treatment Be Initiated?
  • Individualized Approaches to Treatment Selection for Induction Therapy
  • Transplant, Consolidation, and Maintenance: The Role of MRD in Monitoring
  • Therapeutic Strategies After First Relapse Following Initial Therapy
  • Current and Future Options for Therapy in Patients With Late Relapse

Faculty Panel Discussion and Audience Questions
For each case presented, faculty will discuss available clinical data that could guide the treatment choice for the case

Review of a 2018 Treatment Algorithm for MM

3:50 PM – 4:00 PM Final Thoughts and Question and Answer Session
Brian G.M. Durie, MD, Program Director and Moderator


Date / Time
Event Details


Program Director
Brian G.M. Durie, MD

Medical Director, AMyC
Co-Chair Myeloma Committee, SWOG
Chairman, International Myeloma Foundation
Specialist in Multiple Myeloma and Related Disorders
Cedars-Sinai Outpatient Cancer Center
Los Angeles, California

Philippe Moreau, MD

Professor of Clinical Hematology
Hematology Department
University Hospital Hôtel-Dieu
Nantes, France

Bruno Paiva, PhD

Department of Hematology and Immunology
Flow Cytometry Core - CIMA LAB Diagnostics
University of Navarra
Pamplona, Spain

S. Vincent Rajkumar, MD

Edward W. and Betty Knight Scripps Professor of Medicine
Mayo Clinic
Rochester, Minnesota

Jesus San-Miguel, MD, PhD

Director of Clinical and Translational Medicine
Universidad de Navarra
Pamplona, Spain


Goal Statement
The goal of this educational initiative is to improve participants’ competence in and performance at applying practice-changing clinical data and expert recommendations to optimize the care of their patients with multiple myeloma.

Target Audience
This program is intended for physicians and other healthcare providers who care for patients with multiple myeloma.

Learning Objectives

  • Initiate treatment for appropriate patients based on current diagnosis and staging criteria for monoclonal gammopathy of undetermined significance, smoldering MM, and active MM
  • Create individualized treatment strategies for patients with MM through consideration of the available clinical data as well as risk assessment, comorbidities, age/fitness, and patient preferences
  • Integrate the newly approved monoclonal antibodies into existing treatment strategies for patients with MM
  • Plan appropriate treatment strategies using the new-generation proteasome inhibitors for individual patients with MM
  • Consider efficacy and safety evidence of immunomodulatory agents in combination with novel agents to individualize therapeutic strategies for patients with MM
  • Identify ongoing trials of investigational approaches in the treatment of MM to aid referral of patients for study participation


Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
The Annenberg Center for Health Sciences at Eisenhower requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to the Annenberg Center for Health Sciences at Eisenhower policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.